|  |  |  |  |  | mRNA expression in HCV+ vs. HCV-b | Module p-valuec |  | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Module identifier | No. of mRNA | No. of miRNA | miRNA | miRNA gene family | % of overlapped targetsa | log2 ratio | p-value | adj. p-value | P_score | P_Nt | Selected GO terms (BP)d |
miRNA down-regulated, and mRNA up-regulated in HCV+ vs. HCV- | |||||||||||
7 | 48 | 1 | hsa-miR-320 | mir-320 | 56.2 (12.5) | 0.6 | 4.8E-09 | 0.001 | 1.1E-25 | 0 | cell cycle checkpoint |
8 | 34 | 1 | hsa-miR-92 | mir-25 | 44.1 (20.6) | 0.6 | 5.6E-10 | 0 | 1.3E-33 | 0 | actin cytoskeleton organization and biogenesis |
10 | 77 | 1 | hsa-miR-296 | mir-296 | 62.3 (2.6) | 0.8 | 4.3E-15 | 0 | 5.5E-37 | 0 | T cell receptor signaling pathway |
29 | 37 | 1 | hsa-miR-193b | mir-193 | 43.2 (2.7) | 0.6 | 3.9E-08 | 0 | 3.3E-33 | 0 | regulation of apoptosis |
30 | 39 | 1 | hsa-miR-181b | mir-181 | 59 (5.1) | 1.0 | 5.8E-24 | 0 | 2.8E-22 | 0.03 | cell cycle checkpoint |
37 | 46 | 1 | hsa-miR-422b | mir-378 | 39.1 (2.2) | 0.5 | 6.4E-07 | 0 | 8.1E-26 | 0 | B cell differentiation |
39 | 74 | 1 | hsa-miR-122a | mir-122 | 51.4 (1.4) | 0.5 | 1.7E-05 | 0.011 | 1.4E-44 | 0.01 | DNA repair |
50 | 11 | 2 | hsa-miR-122a, hsa-miR-320 | mir-122, mir-320 | 54.5 (0) | 0.8 | 4.9E-13 | 0 | 1.3E-56 | 0 | MAPKKK cascade |
87 | 11 | 2 | hsa-miR-193b, hsa-miR-320 | mir-193, mir-320 | 31.8 (0) | 0.5 | 2.1E-06 | 0.001 | 2.8E-53 | 0 | cell cycle checkpoint |
miRNA up-regulated, and mRNA down-regulated in HCV+ vs. HCV- | |||||||||||
1 | 52 | 1 | hsa-miR-130a | mir-130 | 46.2 (19.2) | -0.5 | 2.3E-05 | 0.016 | 6.5E-15 | 0.02 | regulation of Rho protein signal transduction |
2 | 66 | 1 | hsa-miR-26b | mir-26 | 60.6 (13.6) | -0.7 | 3.6E-08 | 0 | 7.9E-32 | 0 | actin cytoskeleton organization and biogenesis |
4 | 191 | 1 | hsa-miR-16 | mir-15 | 54.5 (18.3) | -0.8 | 2.5E-09 | 0 | 2.6E-46 | 0 | insulin receptor signaling pathway |
13 | 51 | 1 | hsa-miR-21 | mir-21 | 49 (5.9) | -0.6 | 7.6E-07 | 0.002 | 3.8E-33 | 0 | inactivation of MAPK activity |
15 | 170 | 1 | hsa-miR-26a | mir-26 | 62.4 (17.1) | -0.6 | 6.4E-07 | 0.002 | 4.8E-50 | 0 | insulin receptor signaling pathway |
16 | 22 | 1 | hsa-miR-155 | mir-155 | 54.5 (4.5) | -0.6 | 7.7E-10 | 0 | 4.7E-17 | 0.02 | B cell differentiation |
18 | 59 | 2 | hsa-miR-26a, hsa-miR-26b | mir-26 | 62.7 (15.3) | -0.6 | 3.2E-07 | 0.001 | 7.8E-85 | 0 | innate immune response |
27 | 86 | 1 | hsa-miR-215 | mir-192 | 43 (1.2) | -0.7 | 1.8E-07 | 0.002 | 8.2E-32 | 0 | insulin receptor signaling pathway |
28 | 21 | 2 | hsa-miR-16, hsa-miR-215 | mir-15, mir-192 | 38.1 (9.5) | -0.7 | 7.0E-09 | 0 | 2.2E-51 | 0 | apoptotic program |
36 | 37 | 1 | hsa-miR-324-3p | mir-324 | 45.9 (0) | -0.6 | 2.9E-08 | 0 | 2.6E-07 | 0 | cAMP-mediated signaling |
43 | 88 | 1 | hsa-miR-202 | mir-202 | 43.2 (13.6) | -0.6 | 2.3E-04 | 0.036 | 5.6E-52 | 0 | apoptotic program |
52 | 82 | 1 | hsa-miR-509 | mir-509 | 50 (1.2) | -0.6 | 1.6E-11 | 0 | 4.8E-60 | 0 | transforming growth factor beta receptor signaling pathway |
55 | 48 | 1 | hsa-miR-424 | mir-322 | 60.4 (20.8) | -0.7 | 1.2E-09 | 0 | 1.3E-13 | 0.02 | nuclear import |
56 | 30 | 2 | hsa-miR-16, hsa-miR-424 | mir-15, mir-322 | 53.3 (23.3) | -0.7 | 1.5E-09 | 0 | 1.1E-58 | 0 | transforming growth factor beta receptor signaling pathway |
57 | 12 | 1 | hsa-miR-191 | mir-191 | 66.7 (0) | -0.6 | 4.0E-07 | 0.002 | 7.8E-51 | 0 | positive regulation of peptidyl-serine phosphorylation |
58 | 15 | 2 | hsa-miR-26a, hsa-miR-424 | mir-26, mir-322 | 66.7 (23.3) | -0.7 | 2.1E-10 | 0 | 1.4E-44 | 0 | transforming growth factor beta receptor signaling pathway |
59 | 19 | 2 | hsa-miR-16, hsa-miR-26a | mir-15, mir-26 | 60.5 (26.3) | -0.7 | 4.4E-11 | 0 | 2.4E-62 | 0 | transforming growth factor beta receptor signaling pathway |
60 | 11 | 3 | hsa-miR-16, hsa-miR-26a, hsa-miR-424 | mir-15, mir-26, mir-322 | 54.5 (33.3) | -0.7 | 5.3E-12 | 0 | 2.5E-67 | 0 | transforming growth factor beta receptor signaling pathway |
63 | 28 | 1 | hsa-miR-199a* | mir-199 | 0 (0) | -0.8 | 5.0E-07 | 0.002 | 2.1E-04 | 0.03 | negative regulation of MAP kinase activity |
73 | 12 | 2 | hsa-miR-16, hsa-miR-509 | mir-15, mir-509 | 66.7 (25) | -0.6 | 2.0E-09 | 0 | 4.2E-55 | 0 | negative regulation of translational initiation |
76 | 28 | 2 | hsa-miR-215, hsa-miR-26a | mir-192, mir-26 | 57.1 (12.5) | -0.6 | 6.7E-07 | 0 | 1.0E-66 | 0 | transforming growth factor beta receptor signaling pathway |
78 | 23 | 2 | hsa-miR-130a, hsa-miR-16 | mir-130, mir-15 | 47.8 (10.9) | -0.4 | 1.3E-07 | 0.001 | 9.6E-63 | 0 | RNA-mediated gene silencing |
79 | 35 | 1 | hsa-miR-146b | mir-146 | 68.6 (2.9) | -0.3 | 5.5E-08 | 0 | 4.7E-14 | 0 | complement activation, alternative pathway |
81 | 23 | 1 | hsa-miR-15b | mir-15 | 30.4 (8.7) | -0.3 | 2.3E-04 | 0.019 | 6.7E-05 | 0.03 | telomere maintenance via telomerase |
94 | 23 | 2 | hsa-miR-202, hsa-miR-509 | mir-202, mir-509 | 56.5 (6.5) | -0.4 | 4.3E-06 | 0.005 | 2.0E-89 | 0 | transforming growth factor beta receptor signaling pathway |
96 | 15 | 2 | hsa-miR-21, hsa-miR-26a | mir-21, mir-26 | 53.3 (23.3) | -0.5 | 1.7E-08 | 0.001 | 1.6E-51 | 0 | MAPKKK cascade |
101 | 11 | 3 | hsa-miR-21, hsa-miR-26a, hsa-miR-26b | mir-21, mir-26 | 54.5 (21.2) | -0.4 | 1.0E-05 | 0.005 | 8.8E-72 | 0 | innate immune response |
102 | 10 | 3 | hsa-miR-215, hsa-miR-26a, hsa-miR-26b | mir-192, mir-26 | 53.3 (20) | -0.6 | 5.9E-07 | 0.003 | 1.4E-75 | 0 | endothelial cell migration |
170 | 10 | 2 | hsa-miR-202, hsa-miR-324-3p | mir-202, mir-324 | 50 (10) | -0.5 | 1.0E-07 | 0.001 | 1.1E-32 | 0 | response to dsRNA |